Ketamine

Search ⌘K Suggest Edit Sign in Chemistry Pharmacology Therapeutic Uses in Medicine Veterinary Uses Safety and Risks Dependence and Addiction Potential Neurotoxicity Debates Drug Interactions Recreational and Non-Medical Use Legal and Regulatory Status History Current Research and Controversies References Fact-checked by Grok 4 months ago Ketamine Ketamine is a racemic mixture of two enantiomers, (S)-ketamine and (R)-ketamine, synthesized in 1962 by Calvin L. Stevens at Parke-Davis Laboratories as a derivative of phencyclidine, designed to provide dissociative anesthesia with reduced hallucinogenic effects compared to its predecessor.[1][2] Approved by the FDA in 1970 for human and veterinary use, it acts primarily as a non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, inducing a trance-like state of dissociative anesthesia characterized by analgesia, sedation, and amnesia while preserving respiratory drive and airway reflexes.[3][4] In clinical practice, ketamine remains a cornerstone for procedural sedation in emergencies, rapid sequence intubation, and anesthesia in resource-limited or high-risk settings, such as pediatric and battlefield medicine, due to its hemodynamic stability and bronchodilatory properties.[3][1] Beyond anesthesia, low-dose infusions have demonstrated rapid antidepressant effects in treatment-resistant major depression, with studies showing significant symptom reduction within hours to days, outperforming traditional therapies in speed though with variable durability.[5][6] The S-enantiomer, esketamine, received FDA approval in 2019 as a nasal spray adjunct for depression, highlighting ketamine's role in addressing unmet needs in psychiatry, while racemic ketamine's off-label use persists amid ongoing research into mechanisms like enhanced synaptic plasticity via AMPA receptor activation.[7][8] Recreational misuse, often termed "K" or "Special K," exploits its dissociative and hallucinogenic properties at subanesthetic doses, leading to perceptual distortions and the "K-hole" experience, but carries risks including acute neurobehavioral toxicity, psychological dependence, and chronic urinary tract damage akin to cystitis from repeated exposure.[9][10] Despite these hazards, empirical evidence underscores ketamine's unique pharmacological profile—encompassing analgesia for chronic neuropathic pain and potential in conditions like epilepsy—positioning it as a versatile agent whose benefits must be weighed against abuse potential and side effects like emergence delirium.[11][12] Ongoing studies differentiate the enantiomers' effects, with R-ketamine showing promise for sustained antidepressant action with fewer psychotomimetic side effects than S-ketamine.[13][14] Chemistry Structure and Synthesis Ketamine has the molecular formula C₁₃H₁₆ClNO and the IUPAC name 2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one.[15][16] It belongs to the class of arylcyclohexylamines, featuring a cyclohexanone ring substituted at the 2-position with a 2-chlorophenyl group and a methylamino group.[15] The molecule contains a chiral center at the 2-position of the cyclohexanone, resulting in two enantiomers: (S)-ketamine (esketamine) and (R)-ketamine (arketamine).[7] The (S)-enantiomer binds more potently to NMDA receptors, conferring approximately four times the anesthetic and analgesic potency of the (R)-enantiomer.[17] In contrast, (R)-ketamine demonstrates reduced affinity for NMDA receptors but exhibits potentially superior antidepressant effects in preclinical models, with longer duration and fewer dissociative side effects such as psychotomimesis.[7][14] Pharmaceutical ketamine is typically administered as a racemic mixture (50:50 S:R), though esketamine is available as the isolated (S)-enantiomer for specific indications.[7] Ketamine was first synthesized in 1962 by Calvin L. Stevens at Parke-Davis Laboratories as a structural analog of phencyclidine, aimed at developing a safer dissociative anesthetic.[2][18] The original synthesis, detailed in U.S. Patent 3,254,124, involved multi-step construction of the aminocyclohexanone core through imine formation, cyclization, and amination reactions starting from o-chlorobenzonitrile and cyclic ketone precursors.[19] Modern industrial routes often employ similar strategies, including Grignard addition to nitriles, ring expansion of cyclopentanone derivatives, and selective reduction or amination to install the methylamino group.[20] Enantioselective synthesis or chromatographic resolution is required for isolating pure (S)- or (R)-ketamine, as the racemic form arises naturally from achiral synthetic conditions.[7] Detection Methods Ketamine is commonly detected and quantified using chromatographic techniques coupled with mass spectrometry, which provide high sensitivity and specificity for identifying the compound and its metabolites in various matrices such as biological fluids, seized drug samples, and environmental specimens.[21] Gas chromatography-mass spectrometry (GC-MS) in selected ion monitoring mode serves as a precise method for ketamine analysis, capable of detecting concentrations as low as 1 ng/mL in plasma with excellent reproducibility and accuracy after derivatization to enhance volatility.[22] This technique is particularly effective for volatile derivatives of ketamine and norketamine, enabling rapid screening in under 20 minutes per sample with sensitivity exceeding 98% and high specificity when applied to urine or blood.[23] Liquid chromatography-tandem mass spectrometry (LC-MS/MS) offers advantages for polar metabolites like norketamine and dehydronorketamine, avoiding the need for derivatization and allowing achiral quantification in human plasma or oral fluid with limits of detection in the ng/mL range.[24] Dispersive liquid-liquid microextraction (DLLME) combined with LC-MS/MS has been validated for trace-level detection of ketamine analogs in oral fluid, emphasizing green analytical approaches with minimal solvent use.[25] For non-chromatographic alternatives, electrochemical sensors using screen-printed electrodes detect ketamine in street samples via voltammetric fingerprints, providing on-site portability without extensive sample preparation.[26] Immunoassays, such as enzyme-linked immunosorbent assay (ELISA), enable initial screening for ketamine in hair or urine, though confirmation via GC-MS or LC-MS is required due to potential cross-reactivity with similar arylcyclohexylamines.[27] In forensic contexts, dried blood spot (DBS) sampling followed by GC-MS or LC-MS assesses ketamine stability on surfaces like fabric or glass, with metabolites detectable after storage at varying temperatures for weeks.[28] These methods collectively ensure reliable identification, prioritizing orthogonal confirmation to mitigate false positives from structural analogs.[29] Detection times of ketamine and its metabolites in biological fluids vary depending on the administered dose, route of administration, individual factors (including metabolism rate, body mass, hydration status, and urine pH), exact dose administered, and analytical test sensitivity or cutoff levels (e.g., immunoassay screening versus confirmatory GC-MS or LC-MS/MS). For a single therapeutic dose (typically 0.5–1 mg/kg administered sublingually or intramuscularly), ketamine is generally detectable in blood for up to 24 hours, with its primary metabolite norketamine detectable for up to 48–72 hours. In urine, ketamine and norketamine are generally detectable for 2–5 days following single use, typically on the shorter end (2–4 days) for low therapeutic doses, although highly sensitive testing can extend detection to 14 days in some cases. These windows are shorter compared to those associated with recreational or chronic high-dose use due to the substantially lower doses employed in therapeutic applications. The sublingual and intramuscular routes exhibit similar pharmacokinetics with respect to elimination and resulting detection times.[30] Pharmacology Pharmacodynamics Ketamine primarily functions as a non-competitive, uncompetitive antagonist at N-methyl-D-aspartate (NMDA) receptors, binding within the receptor's ion channel as an open-channel blocker to inhibit glutamate-evoked cation (Na⁺, K⁺, Ca²⁺) influx in a voltage- and use-dependent fashion.[31] This action, occurring at clinically relevant concentrations of 2–50 μM, underlies its hallmark dissociative anesthetic effects, including analgesia, amnesia, psychosensory disturbances, and neuroprotection against excitotoxic damage.[4] The blockade preferentially targets NMDA receptors containing GluN2C subunits on GABAergic interneurons at low micromolar doses, reducing inhibitory tone and enhancing excitatory signaling in downstream pathways.[31] Beyond NMDA receptors, ketamine exhibits affinity for diverse targets, including μ-, δ-, and κ-opioid receptors; monoaminergic systems via inhibition of norepinephrine, serotonin, and dopamine reuptake; muscarinic and nicotinic cholinergic receptors; and voltage-sensitive ion channels such as sodium, calcium, and potassium channels.[4] It also inhibits hyperpolarization-activated cyclic nucleotide-gated (HCN1) channels at approximately 10 μM, contributing to hypnotic and sedative properties, with the S-enantiomer showing greater potency in this regard.[31] These multifaceted interactions modulate hypnotic, psychic-emergent, and antinociceptive effects, though their relative contributions vary by dose and context.[4] As a chiral molecule, ketamine is typically administered as a racemic mixture of (S)-(+)-ketamine (esketamine) and (R)-(-)-ketamine (arketamine), with the S-enantiomer possessing 3–4 times higher affinity for the NMDA receptor's phencyclidine site, rendering it approximately twice as potent as the racemate and four times more than the R-form for anesthetic and analgesic outcomes.[4] The S-enantiomer also produces fewer psychodysleptic side effects at equipotent doses.[4] Ketamine's principal metabolite, norketamine (formed via hepatic N-demethylation), retains NMDA antagonistic activity at 20–30% of the parent compound's potency and sustains analgesia into the elimination phase, with detectable effects persisting beyond five hours post-administration.[4] Certain hydroxynorketamine isomers, notably (2R,6R)-hydroxynorketamine, exhibit pharmacodynamic activity independent of NMDA blockade, potentially influencing synaptic plasticity and other therapeutic endpoints.[31] Antidepressant Mechanisms Ketamine exhibits rapid-acting antidepressant effects at subanesthetic doses (typically 0.2–0.5 mg/kg IV infused over 40 minutes), with symptom improvement often observable within hours, contrasting with the weeks required for traditional antidepressants. This rapid action is primarily mediated by NMDA receptor antagonism on GABAergic interneurons in the prefrontal cortex, leading to disinhibition of pyramidal neurons and a transient surge in glutamate release. The elevated glutamate activates postsynaptic AMPA receptors, which triggers calcium influx and initiates intracellular signaling cascades, including increased expression and release of brain-derived neurotrophic factor (BDNF) and activation of its receptor TrkB. This in turn stimulates the mechanistic target of rapamycin complex 1 (mTORC1) pathway, promoting protein synthesis, dendritic spine growth, synaptogenesis, and enhanced synaptic plasticity in key mood-regulating circuits. These neuroplastic changes are believed to reverse the synaptic deficits associated with depression.[32][33] Emerging evidence points to additional mechanisms contributing to ketamine's antidepressant efficacy. A 2025 study published in Nature revealed that ketamine increases intracellular adenosine levels through modulation of cellular metabolism, without causing neuronal hyperactivity, and that adenosine signaling acts as a central driver of the rapid antidepressant effects shared between ketamine and electroconvulsive therapy (ECT).[34] A 2025 review in the American Journal of Psychiatry argues for redefining ketamine's pharmacology to include significant interactions with opioid receptors and the endogenous opioid system, proposing that these contribute synergistically with NMDA antagonism to its antidepressant properties.[35] The major metabolite (2R,6R)-hydroxynorketamine ((2R,6R)-HNK) demonstrates potential antidepressant activity independent of NMDA receptor blockade, with preclinical and phase 1 clinical data indicating robust effects in models of depression alongside a favorable safety profile lacking dissociative or psychotomimetic side effects.[36][37] These mechanisms exhibit clear dose-dependence: low therapeutic doses preferentially engage neuroplasticity pathways for antidepressant benefits, while higher doses shift toward dissociative and anesthetic effects through broader NMDA blockade and off-target actions. In January 2025, the U.S. FDA expanded the approval of intranasal esketamine (Spravato) to include monotherapy for adults with treatment-resistant depression, marking it as the first and only standalone pharmacologic treatment for this indication (previously approved only as an adjunct to oral antidepressants).[38][39] Pharmacokinetics Ketamine exhibits rapid absorption following intravenous (IV) administration, with peak plasma concentrations achieved almost immediately and an onset of action within seconds to minutes.[3] Intramuscular (IM) injection results in quick absorption and high bioavailability of approximately 93%, with onset in 0.5 to 2 hours.[40] Oral administration is characterized by extensive first-pass metabolism in the liver, yielding low bioavailability of about 17%, which delays onset to 1 to 6 hours or more.[40] Sublingual administration via troches yields a bioavailability of approximately 20–25%.[41] Intranasal routes also provide reasonable absorption, though with variable bioavailability depending on formulation.[4] Rectal (intrarectal) administration yields a bioavailability of approximately 25-30%, lower than intravenous (near 100%) or intramuscular (93%) routes due to partial first-pass metabolism and incomplete absorption.[3] Distribution of ketamine is extensive due to its high lipid solubility, with a volume of distribution around 3 L/kg and rapid tissue penetration, including the brain.[42] Protein binding ranges from 23% to 47%.[40] A redistribution half-life of 11 to 16 minutes contributes to its short duration of intense effects despite a longer elimination phase.[43] Ketamine undergoes hepatic metabolism primarily via cytochrome P450 enzymes, with CYP3A4 as the main contributor, followed by CYP2B6 and CYP2C9.[3] N-demethylation produces norketamine, an active metabolite with approximately one-third the potency of the parent drug, alongside dehydronorketamine and hydroxynorketamine.[44] These metabolites may contribute to prolonged effects, such as in antidepressant activity.[45] Elimination follows a two- or three-compartment pharmacokinetic model, with an elimination half-life of 2 to 3 hours for ketamine and up to 12 hours for norketamine.[4] Clearance is high, at 890 to 1227 mL/min, and excretion occurs predominantly via urine (91%), with fecal elimination accounting for 3%; only about 2% of unchanged ketamine is excreted renally.[3] Most output consists of conjugated metabolites.[44] Pharmacokinetics can vary by patient factors, such as higher clearance in females or altered profiles in intensive care settings with increased volume of distribution.[4][46] Dose-Response Relationships Ketamine's pharmacological effects demonstrate a steep dose-response profile, with distinct therapeutic windows for analgesia, anesthesia, and neuropsychiatric applications, alongside increasing risks of dissociation and cardiovascular stimulation at higher doses. Sub-dissociative doses (typically 0.1–0.5 mg/kg IV) produce analgesia and rapid antidepressant effects without full loss of consciousness, primarily via NMDA receptor antagonism and downstream modulation of glutamatergic signaling.[47][48] As doses escalate to 1–2 mg/kg IV, dissociative anesthesia emerges, characterized by catalepsy, analgesia, and preserved airway reflexes, though psychotomimetic symptoms like hallucinations intensify in a dose-dependent manner.[3][49] Full induction of anesthesia requires 1–4.5 mg/kg IV, yielding profound dissociation and immobility for 5–15 minutes, with recovery influenced by redistribution rather than metabolism.[50][51] Effect Category Typical IV Dose (mg/kg) Duration and Key Outcomes Citation Analgesia (sub-dissociative) 0.1–0.5 Acute pain reduction without sedation; opioid-sparing effects [47] [52] Antidepressant 0.2–0.5 (infusion over 40 min) Rapid symptom relief in treatment-resistant depression; effects peak within hours [53] [54] Dissociative sedation 0.5–2 Sensory isolation, mild psychotomimesis; used in procedural sedation [3] [49] Anesthetic induction 1–4.5 Full dissociation, analgesia, cardiovascular stability; 5–10 min duration [55] [56] Higher doses correlate with amplified adverse effects, including hypertension (via sympathetic stimulation) and emergence delirium, which occur more frequently above 2 mg/kg, necessitating benzodiazepine co-administration for mitigation.[57][3] Pharmacodynamic modeling indicates that plasma concentrations of 100–600 ng/mL suffice for subanesthetic analgesia and mood elevation, while anesthetic levels exceed 1,000 ng/mL, with individual variability influenced by CYP2B6 metabolism and route of administration (e.g., IM doses of 3–10 mg/kg for prolonged effects).[4] Esketamine, the S-enantiomer, exhibits similar but potentially more potent dose-response curves for antidepressant action at equivalent molar doses, though racemic ketamine remains standard for anesthesia due to broader efficacy data.[58] Empirical studies underscore non-linear responses, where doubling subanesthetic doses (e.g., from 0.5 to 1 mg/kg) yields diminishing antidepressant returns alongside heightened dissociation, supporting personalized titration over fixed escalation.[59][60] Therapeutic Uses in Medicine Anesthesia Ketamine functions as a dissociative anesthetic, inducing a trance-like state where patients experience analgesia, sedation, and amnesia while maintaining protective airway reflexes and spontaneous respiration.[3] Unlike traditional anesthetics such as propofol or opioids, it does not typically cause respiratory depression or significant hypotension, owing to its sympathomimetic effects that elevate heart rate and blood pressure.[61] This profile renders it particularly suitable for induction and maintenance of anesthesia in hemodynamically unstable patients, pediatric procedures, and resource-limited environments where monitoring and supportive equipment may be inadequate.[62] The U.S. Food and Drug Administration approved ketamine hydrochloride for human medical use on February 13, 1970, primarily for anesthesia induction and maintenance, either alone or supplemented with other agents.[63] Clinically, intravenous doses of 1 to 2 mg/kg achieve surgical anesthesia within 30 to 60 seconds, lasting 5 to 10 minutes, while intramuscular administration at 4 to 5 mg/kg provides onset in 3 to 4 minutes and duration up to 15 minutes.[3] Maintenance infusions range from 0.1 to 0.5 mg/kg/hour, often combined with benzodiazepines to mitigate psychotomimetic emergence reactions such as hallucinations or agitation, which occur in up to 30% of cases without adjuncts.[48] The Society of Critical Care Medicine endorses its use in rapid sequence intubation for critically ill patients, citing preserved respiratory drive and bronchodilation beneficial in asthmatics.[3] Advantages include cardiovascular stability, making it preferable in trauma or shock scenarios, as evidenced by its historical deployment in military settings for battlefield anesthesia without requiring intubation.[61] It supports skeletal muscle tone and laryngeal reflexes, reducing aspiration risk compared to GABAergic agents.[62] However, contraindications encompass uncontrolled hypertension, elevated intracranial pressure (due to potential cerebral vasodilation), and thyrotoxicosis, with caution advised in glaucoma or psychiatric disorders prone to exacerbation by dissociative states.[3] Adverse effects during anesthesia include transient hypertension (up to 20-50 mmHg systolic increase), tachycardia, hypersalivation (necessitating anticholinergics like atropine), and rare laryngospasm.[64] Long-term repeated exposure in neonates or fetuses has shown neuronal apoptosis in animal models, prompting warnings against prolonged use in pregnancy.[63] In procedural sedation, sub-anesthetic doses (0.3-0.5 mg/kg IV) provide effective analgesia and amnesia for short interventions like fracture reduction, with recovery times under 15 minutes.[65] Consensus guidelines emphasize monitoring for emergence delirium, recommending co-administration of midazolam to attenuate it without prolonging recovery.[48] Despite these benefits, ketamine's psychotomimetic properties limit its standalone use in elective surgery, favoring multimodal regimens in modern practice.[62] \n Use in resource-limited, humanitarian, and field settings Ketamine is widely regarded as a cornerstone anesthetic agent in resource-limited settings, humanitarian medical missions, disaster response, and battlefield medicine due to its favorable pharmacological profile. It provides dissociative anesthesia with preserved airway reflexes, respiratory drive, and hemodynamic stability, without requiring compressed oxygen, volatile gas delivery systems, or sophisticated monitoring equipment—making it ideal for austere environments where infrastructure is minimal or unreliable. In low- and middle-income countries (LMICs) and during short-term surgical missions, ketamine is frequently used as a sole anesthetic or in total intravenous anesthesia (TIVA) protocols, enabling procedures ranging from trauma surgery to obstetrics in areas lacking anesthesiologists or advanced resources. Organizations such as Médecins Sans Frontières (MSF) and military field units have long relied on it for these reasons. However, obtaining and transporting ketamine for such missions presents significant regulatory hurdles, particularly from high-regulation countries like the United States: US classification and export controls: As a Schedule III controlled substance under the DEA's Controlled Substances Act, ketamine requires strict registration, security, and record-keeping. For humanitarian medical missions, export is generally restricted to DEA-registered exporters; small groups or individuals cannot legally ship it without compliance. The DEA is developing specific guidelines for medical missions, but currently, unregistered parties must utilize licensed exporters. FDA donation guidelines: The FDA discourages donations of drugs (including ketamine) from individuals or small groups for international relief, citing risks of non-compliance with safety, efficacy, and quality standards. Donations should be large-scale, requested by the recipient country or recognized relief organizations, and meet export requirements under the Federal Food, Drug, and Cosmetic Act. International status: Ketamine remains unscheduled under the UN's 1961 Single Convention on Narcotic Drugs, 1971 Convention on Psychotropic Substances, and 1988 Convention against Illicit Traffic, following repeated WHO recommendations against international control (e.g., 2015 ECDD review) to avoid impeding access in LMICs where it is essential and affordable. Experienced mission teams typically procure ketamine through local or regional suppliers in the host country (where it is often readily available for medical use) or via established NGOs with compliant supply chains, rather than attempting personal transport. Individuals or unofficial groups face high risks of customs seizure, legal penalties, or confiscation when attempting to carry it in luggage, even with documentation. These factors underscore ketamine's dual role as a critically important essential medicine in global health equity efforts and a tightly regulated controlled substance requiring careful logistical planning for cross-border humanitarian use. Formulations and administration Ketamine is commercially available as ketamine hydrochloride injection, a clear, colorless, sterile solution for intravenous or intramuscular use. It is supplied predominantly in multiple-dose (multi-dose) vials containing a preservative to inhibit bacterial growth after initial puncture. Common formulations include: 10 mg/mL (equivalent to 200 mg/20 mL vial), often isotonic with sodium chloride. 50 mg/mL (equivalent to 500 mg/10 mL vial). 100 mg/mL (equivalent to 500 mg/5 mL or 1,000 mg/10 mL vial), typically a concentrate requiring dilution before intravenous administration. These vials include not more than 0.10 mg/mL benzethonium chloride as a preservative in water for injection. The solution has a pH of 3.5 to 5.5. Multi-dose vials are intended for multiple entries using aseptic technique. According to manufacturer guidelines and CDC recommendations, they should be discarded after 28 days from first puncture, if contamination is suspected, or per the labeled beyond-use date. Single-dose vials exist but are less common for standard ketamine hydrochloride injection. Ketamine hydrochloride injection is classified as a Schedule III controlled substance (CIII) in the United States, requiring regulated handling and dispensing. For specific dosing and administration, refer to clinical guidelines and product-specific prescribing information. Compounded ketamine for intranasal use is custom-prepared by pharmacies, often at higher concentrations (e.g., 100–200 mg/mL, with noted variability in the 125–200 mg/mL range) compared to FDA-approved injectable ketamine hydrochloride (typically 50 mg/mL or 100 mg/mL). Nasal formulations may include adjustments like altered pH or additives to reduce mucosal irritation, which are not optimized for injection. These products are not sterile to injectable standards, posing risks of infection, abscesses, or systemic complications if administered intramuscularly. Additionally, the high bioavailability of IM administration (~93%) versus intranasal (~25–50%) means injecting a nasal-intended dose could deliver a significantly higher effective amount, risking overdose, intense dissociation, hemodynamic instability, or other adverse effects. The FDA has issued alerts in February 2022 (https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-professionals-potential-risks-associated-compounded-ketamine-nasal-spray) and October 2023 (https://www.fda.gov/drugs/human-drug-compounding/fda-warns-patients-and-health-care-providers-about-potential-risks-associated-compounded-ketamine) on compounded ketamine nasal products, highlighting risks including variable potency, lack of standardized safety data, and increased potential for adverse events with unmonitored use. Repurposing compounded nasal ketamine for IM injection is unsafe and not supported by any regulatory guidance; only pharmaceutical-grade injectable formulations should be used for IM administration under medical supervision. Pain Management Ketamine serves as an adjunct analgesic in acute pain management, particularly in perioperative and emergency settings, where it reduces opioid consumption and postoperative pain scores. A 2018 systematic review of randomized controlled trials found that perioperative ketamine administration decreased opioid requirements by approximately 20-40% across various surgical procedures, with evidence strongest for procedures involving significant nociceptive input like spinal fusion or major abdominal surgery.[66] This effect stems from ketamine's non-competitive antagonism of NMDA receptors, which interrupts central sensitization and wind-up phenomena in dorsal horn neurons.[67] Low-dose ketamine (0.1-0.5 mg/kg bolus followed by infusion) has been deemed safe and effective for acute pain in emergency departments, often allowing opioid-sparing strategies in opioid-tolerant patients or those at risk of respiratory depression.[47] In chronic pain, ketamine is administered off-label via low-dose intravenous infusions (typically 0.1-0.3 mg/kg/hour over several hours or days) for refractory conditions such as neuropathic pain, complex regional pain syndrome, and fibromyalgia, though clinical evidence remains conflicting. A 2003 evidence-based review classified ketamine's efficacy for chronic pain as moderate to weak, recommending its use only after failure of standard therapies due to inconsistent trial outcomes and small sample sizes.[68] A 2022 meta-analysis of neuropathic pain trials reported statistically significant short-term pain reduction with ketamine adjunct therapy compared to standard treatments alone, with effect sizes indicating moderate benefit in select subgroups.[69] However, a 2025 Cochrane systematic review of 14 randomized trials involving 785 participants found no clear evidence of sustained pain relief from ketamine for non-cancer chronic pain, alongside elevated risks of hallucinations, delusions, and other psychotomimetic effects.[70] Real-world applications highlight variability; a October 2025 Cleveland Clinic study of over 1,000 chronic pain patients undergoing standardized low-dose infusions (mean total dose 0.5-1 mg/kg per session) demonstrated significant pain score reductions (average 2-3 points on a 10-point scale) lasting weeks to months, with adverse events primarily mild and transient, such as dizziness or nausea in under 20% of cases.[71] Conversely, the U.S. Department of Veterans Affairs' 2024 clinical determination cited insufficient peer-reviewed evidence for routine use in chronic pain, emphasizing methodological flaws in existing studies like heterogeneous dosing and short follow-up periods.[72] For cancer-related pain, a 2023 randomized trial showed ketamine infusions reduced breakthrough pain intensity without increasing nausea or vomiting compared to placebo, supporting its role in palliative care for opioid-refractory cases.[73] Guidelines from bodies like the American Society of Anesthesiologists endorse ketamine for acute procedural sedation and analgesia but caution against broad chronic use absent robust randomized data, prioritizing patient selection to minimize risks such as hypertension or dissociative symptoms.[67] Overall, while ketamine offers mechanistic advantages in preventing opioid-induced hyperalgesia, its chronic application requires careful monitoring and is not first-line due to evidentiary gaps and potential for tolerance development.[74] Depression and Suicidality In psychiatry, subanesthetic racemic ketamine infusions are used off-label for treatment-resistant depression (TRD), providing rapid antidepressant effects via NMDA antagonism and downstream neuroplasticity. Meta-analyses (Bahji et al., 2021/2022) show superior response (RR=3.01 vs 1.38) and remission (RR=3.70 vs 1.47) compared to intranasal esketamine, with faster onset in some head-to-head data (e.g., 2025 study: 49% vs 39% MADRS reduction). Esketamine (S-enantiomer) is FDA-approved (Spravato) with higher NMDA affinity but more modest effect sizes in trials. Racemic may engage additional pathways via R-enantiomer. Long-term data favor esketamine due to regulatory studies, but IV racemic shows promise in acute severe cases. Emerging oral formulations (e.g., R-107) offer convenience with positive phase trials. Ketamine, administered at subanesthetic doses, has demonstrated rapid antidepressant effects in patients with treatment-resistant depression (TRD), often within hours of a single intravenous infusion, with response rates exceeding 50% in some clinical trials.[75][76] Repeated infusions, typically 0.5 mg/kg over 40 minutes, sustain these effects for weeks, outperforming active placebos like midazolam in randomized controlled trials.[77] In a 2023 multicenter trial, ketamine showed efficacy comparable to electroconvulsive therapy (ECT) for nonpsychotic TRD, achieving remission in approximately 55% of participants after three weeks, but without ECT's cognitive side effects.[6][78] The S-enantiomer, esketamine, formulated as a nasal spray (Spravato), received FDA approval on March 5, 2019, for treatment-resistant depression (TRD) in adults in conjunction with an oral antidepressant, and as monotherapy for TRD in 2025, based on phase 3 trials showing sustained symptom reduction over four weeks.[79] On August 3, 2020, the FDA expanded approval to include major depressive disorder (MDD) with acute suicidal ideation or behavior, reflecting evidence of rapid reductions in suicidal thoughts within 24 hours.[80][81][82] In the United States, the Department of Veterans Affairs (VA) provides intravenous ketamine and esketamine (Spravato) for eligible veterans with treatment-resistant depression (TRD), generally requiring prior failure of multiple antidepressants and severe symptoms.[83][84] Studies in veteran populations have shown significant improvements, with 70-86% experiencing reductions in depression scores and suicidal ideation.[85] The Department of Defense (DoD) approves esketamine for TRICARE beneficiaries, including active-duty military, with TRD on a case-by-case basis with prior authorization.[86] No specific US Army-only program exists, with coverage through VA for veterans and DoD/TRICARE for active-duty personnel. Off-label, sublingual ketamine troches are used for at-home administration in TRD; patients place the troche under the tongue to dissolve fully over 15-30 minutes, retain saliva, and spit out any remainder to minimize gastrointestinal absorption, while avoiding eating, drinking, or other medications for 1 hour before and after dosing and refraining from driving or operating machinery for several hours afterward.[87] However, trials indicate that while esketamine lowers suicidal ideation scores, it does not conclusively prevent suicide or eliminate ongoing risk, as relapses and attempts have occurred post-treatment.[88][89] Both enantiomers contribute to antidepressant effects, with evidence suggesting the R-enantiomer may activate unique pathways independent of NMDA antagonism, potentially enhancing efficacy in the racemic mixture. Mechanistically, ketamine's antidepressant action stems from non-competitive antagonism of NMDA receptors, preferentially on GABAergic interneurons, leading to a glutamate surge, AMPA receptor activation, and enhanced synaptic plasticity via mTOR signaling and BDNF release.[90][91] This contrasts with traditional antidepressants' monoamine-based delays of weeks, enabling ketamine's onset in as little as 40 minutes, though effects wane after 7-14 days without maintenance dosing.[33][92] Despite short-term efficacy, limitations include transient benefits requiring ongoing infusions or sprays, with relapse rates up to 50% within months, and insufficient long-term data on safety beyond one year in therapeutic contexts.[93][94] Acute risks encompass dissociation, elevated blood pressure, and sedation, as well as transient restlessness, feeling "wired", or short-term insomnia in some individuals; these effects are typically short-lived, lasting from a few hours to 1-2 days, with most resolving within 24 hours, and prolonged insomnia is not a commonly reported or prominent side effect in therapeutic contexts, while potential for abuse and dependence persists due to its dissociative properties; chronic recreational use, not therapeutic dosing, links to neurotoxicity like reduced gray matter volume.[95][96] Esketamine's REMS program mandates clinic administration and monitoring to mitigate misuse, underscoring unresolved questions on durability and cognitive impacts in extended use.[80][97] A 2023 meta-analysis by Nikolin et al. found that racemic ketamine produced numerically greater effect sizes than intranasal esketamine for depression severity, response rates, and remission in patients with treatment-resistant depression. Comparative studies generally indicate superior efficacy for intravenous racemic ketamine over esketamine, though esketamine offers regulatory approval and ease of use. In clinical practice, intravenous (IV) racemic ketamine is commonly regarded as the most popular and widely used form in specialized ketamine clinics for treatment-resistant depression due to its extensive research backing, precise dosing control, cost-effectiveness in some settings, and evidence from real-world studies showing faster onset and greater symptom reduction compared to intranasal esketamine in certain comparisons (e.g., a 2025 retrospective chart review of 153 patients demonstrated that IV ketamine achieved a 49.22% reduction in QIDS-SR16 depression scores by the end of treatment, compared to 39.55% for intranasal esketamine, with IV improvements often evident after the first treatment). Although esketamine (Spravato nasal spray) remains the only FDA-approved ketamine-derived treatment for depression—approved for treatment-resistant depression (TRD) in conjunction with an oral antidepressant since 2019 and as monotherapy since 2025—off-label use of IV racemic ketamine continues to be prevalent in clinical practice. The choice of treatment form depends on factors such as patient preference, insurance coverage, and clinic availability. The antidepressant effects of low-dose ketamine in treatment-resistant depression are rapid but typically transient. A single subanesthetic intravenous infusion (e.g., 0.5 mg/kg) often produces significant symptom reduction within hours, peaking around 24 hours, with effects commonly lasting 3-7 days before fading, and relapse occurring within 1-2 weeks in many patients. This limited durability stems from the temporary nature of ketamine-induced neuroplasticity: it triggers a surge in glutamate release, AMPA receptor activation, BDNF release, and mTOR pathway signaling, leading to rapid formation of new dendritic spines and synapses in regions like the prefrontal cortex and hippocampus. However, preclinical studies show that many of these new spines disappear within days if not reinforced, allowing depressive circuits to re-emerge. Repeated infusions, such as a series of 4-6 administered 2-3 times per week over 2-4 weeks, yield cumulative synaptogenesis and more sustained circuit restoration, with higher response rates (up to 70%) and extended benefits during and shortly after the series. Even so, median time to relapse after the final infusion is approximately 18-19 days without ongoing maintenance. Maintenance dosing (e.g., weekly to monthly boosters) or adjunctive psychotherapy during the post-infusion neuroplasticity window (peaking 24-72 hours, when the brain is highly adaptable) can help prolong remission by reinforcing adaptive changes and preventing reversion to atrophied states. Individual factors like depression severity, BDNF genetics, and concurrent therapy influence outcomes. In monitored psychiatric settings, the safety profile features transient dissociation and mild hemodynamic effects, with no major cumulative neurotoxic or other severe issues reported in therapeutic contexts. === Therapeutic dosages for depression === Ketamine is used off-label (racemic) or as FDA-approved esketamine for treatment-resistant depression (TRD). ==== Intravenous (IV) infusion ==== Standard: 0.5 mg/kg over 40 minutes (range 0.1-0.75 mg/kg). For 70 kg person: ~35 mg. Induction: 2-3x/week for 2-4 weeks (4-8 sessions). Maintenance: Weekly to monthly. Bioavailability: 100%. Onset: Rapid (hours). Most studied, highest efficacy. ==== Intranasal esketamine (Spravato) ==== FDA-approved. Doses: 56 mg or 84 mg (2-3 devices of 28 mg). TRD induction: Twice weekly weeks 1-4 (start 56 mg), then once weekly weeks 5-